MedTrace Logo

Tissue Procurement Substudy for Participants in Study CP-MGA271-01

NCT01918930 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-02-08

No results posted yet for this study

Summary

The purpose of this study is to gain a better understanding about how the study drug MGA271 works. No test drug will be given in this study. Patients with easily accessible tumors at the screening visit for participation in Study CP-MGA271-01 will be asked to participate in this substudy. Patients will undergo two excisional biopsies, punch biopsies, or core needle biopsies.

Conditions

Interventions

BIOLOGICAL

MGA271

MGA271 anti-B7-H3 monoclonal antibody

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • MacroGenics

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · MacroGenics

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01918930 on ClinicalTrials.gov